$1.42+0.01 (+0.71%)
Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products.
Hyperfine, Inc. in the Healthcare sector is trading at $1.42 with a market capitalization of $148M. Wall Street consensus targets $2.17 (3 analysts), implying a +52.6% move over the next 12 months. The stock is currently 36% below its 52-week high of $2.22, remaining 12.7% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than...
Shares of Hyperfine (NASDAQ:HYPR) gained 4% in premarket trading on Tuesday after the company announced that it is expected to be added to both the Russell 3000 Index and the Russell 2000 Index. Russell inclusion set to take effect after June reconstitutionThe medical technology company said its inclusion is expected to occur as part of the June 2026 Russell index reconstitution process, based on a preliminary list published by FTSE Russell on May 22, 2026.
Hyperfine Inc (HYPR) reports an 83% revenue increase and international expansion, but faces net losses and cash burn concerns.
Hyperfine (NASDAQ:HYPR) reported a sharp year-over-year increase in first-quarter revenue and reiterated its full-year 2026 outlook, as management pointed to continued adoption of its next-generation Swoop portable MRI system across hospitals, neurology offices and international markets. President
Hyperfine (HYPR) delivered earnings and revenue surprises of 0.00% and +14.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
CVRx (CVRX) delivered earnings and revenue surprises of +1.32% and +3.69%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?